Fungi - Candida albicans - Telomere Research Descriptive Posts - Post 5

 

 Pharmaceutical research targeting ERG11 mutations in Candida albicans, with a focus on nuclear biology, aims to develop novel antifungal agents that can overcome azole resistance. Understanding the specific mechanisms by which ERG11 mutations alter the enzyme's structure and function is crucial for designing drugs that can effectively inhibit the mutated protein. Nuclear chemistry plays a role in elucidating the interactions between potential drug candidates and the mutated ERG11 enzyme at the molecular level.

Comments

Post a Comment

Popular posts from this blog

   At the biochemical level, ERG11 ’s function as a heme-dependent monooxygenase interlocks with the cell’s oxidative balance. Heme fluctuations within the nucleus can alter the activity of heme-responsive transcription factors and chromatin modifiers, introducing a chemical feedback loop between metabolism and genetic variation (Puig & Gutiérrez, 2022). Reactive oxygen species generated by azole stress promote DNA oxidation and base substitution events preferentially within open chromatin domains. This coupling of redox chemistry with mutation formation constitutes a nuclear-scale biochemical evolution engine—one where chemical disequilibrium catalyzes genomic diversity in real time.
Read more

Fungi - Candida auris - Non-Elaborate Posts - Post 2

Genetics and genetic mutations for resistance to fluconazole ERG11 mutations (notably Y132F, K143R) are common contributors to fluconazole resistance; and Cas9 editing showed direct contribution of these alleles to elevated MICs. Additional determinants (TAC1B, efflux pumps, aneuploidy) amplify resistance. Different geographic clades show distinct ERG11 allele frequencies. Genome assemblies reveal structural variation and copy-number differences Resistance evolves under strong antifungal selection in hospitals. Surveillance sequences help track clonal spread and mutation patterns
Read more
In some settings, susceptible-dose dependent (SDD) categorization is used: isolates with intermediate MICs may still respond to higher fluconazole doses, but the presence of ERG11 mutations often reduces the likelihood of clinical success even with dose escalation. ( PMC ) Beyond single substitutions, clinical isolates frequently carry combinations of ERG11 changes plus efflux-regulatory mutations (e.g., TAC1 gain-of-function) that together produce higher MICs and poorer outcomes; thus, sequencing plus expression data can refine prognostic interpretation.
Read more